Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

Summary

Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.

Timeline

Start

2022-03-21

Primary completion

2032-09-30

Completion

2045-09-30

Publications

• Backman AS, Frank A, Lindberg LJ, Ljungman D, Silander G, Gustafsson RJ, Bozso T, Schmidt PT, Ingre M, Mittlbock M, Lowbeer C, Marsal J, Lindblom A, Tham E, Therkildsen C, Gasche C; International MesaCAPP Study Group. Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol. BMJ Open. 2025 Nov 9;15(11):e100082. doi: 10.1136/bmjopen-2025-100082.

Drugs

Indications